About BioTissue
BioTissue is a company based in Miami (United States) founded in 2001 by Amy Tseng and Scheffer CG Tseng. It operates as a Direct-to-Consumer (D2C) and Professional Services. BioTissue has raised $110.04 million across 19 funding rounds from investors including HHS, EW Healthcare Partners and Ballast Point Ventures. BioTissue offers products and services including Prokera, AmnioGraft, Neox 100, and Clarix 100. BioTissue operates in a competitive market with competitors including Annexon, Aldeyra, Nicox, Gyroscope and MeiraGTx, among others.
- Headquarter Miami, United States
- Founders Amy Tseng, Scheffer CG Tseng
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biotissue
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$110.04 M (USD)
in 19 rounds
-
Latest Funding Round
$4.42 M (USD), Grant
Jun 21, 2021
-
Investors
HHS
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of BioTissue
BioTissue offers a comprehensive portfolio of products and services, including Prokera, AmnioGraft, Neox 100, and Clarix 100.
Used for ocular healing with regenerative tissue technology.
Applied in ocular treatments for tissue regeneration support.
Utilized in surgical procedures for regenerative tissue healing.
Employed in surgical applications for tissue repair solutions.
People of BioTissue
Unlock access to complete
Unlock access to complete
Funding Insights of BioTissue
BioTissue has successfully raised a total of $110.04M across 19 strategic funding rounds. The most recent funding activity was a Grant round of $4.42 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in BioTissue
BioTissue has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, EW Healthcare Partners and Ballast Point Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Growth-stage healthcare companies are invested in by EW Healthcare Partners.
|
Locked | Locked | Locked | |
|
Expansion capital is provided by Ballast Point Ventures to growing companies.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for BioTissue
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioTissue
Investment portfolio details for BioTissue
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BioTissue
Detailed financials for BioTissue
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biotissue Comparisons
Peer comparison for BioTissue
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BioTissue
BioTissue operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Annexon, Aldeyra, Nicox, Gyroscope and MeiraGTx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| Locked | Locked | Locked |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| Locked | Locked | Locked |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| Locked | Locked | Locked |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
|
| Locked | Locked | Locked |
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics
|
Detailed competitors of BioTissue
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biotissue
Complete news archive for BioTissue
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioTissue
BioTissue was founded in 2001 and raised its 1st funding round 5 years after it was founded.
BioTissue is headquartered in Miami, United States. It is registered at Miami, Florida, United States.
BioTissue is a funded company, having raised a total of $110.04M across 19 funding rounds to date.
BioTissue is engaged in the development and delivery of regenerative healing solutions using human birth tissue products. The company operates in the healthcare sector, specifically within biotechnology and regenerative medicine. Its offerings include ocular and surgical products such as Prokera, AmnioGraft, Neox, and Clarix, which are designed to support tissue repair and healing. Proprietary technologies like CryoTek are utilized to preserve the natural structure and biology of tissues. Research and development efforts are emphasized, with over 40 years of experience and more than 1 million clinical applications recorded.
BioTissue's top competitors include Annexon, Alimera Sciences and MeiraGTx.
BioTissue offers Prokera, AmnioGraft, Neox 100, and Clarix 100.
BioTissue has 4 investors. Key investors include HHS, EW Healthcare Partners, Ballast Point Ventures, and River Cities Capital.